Document:

Amended and Restated Owens Corning 2006 Stock Plan

 Exhibit 10.1 
 OWENS CORNING 
 2006 STOCK PLAN 
 (As Amended and Restated effective December 6, 2007) 
 I. INTRODUCTION

 1.1 Purpose. The purpose of the Owens Corning Stock Incentive Plan (the “Plan”) is to
promote the long-term financial success of Owens Corning (the “Company”) by (i) establishing a Management Equity Program; (ii) establishing a broad-based Employee Equity Program for all Company employees (other than those
persons eligible to participate in the Management Equity Program); (iii) attracting and retaining executive personnel of outstanding ability; (iv) strengthening the Company’s capability to develop, maintain and direct a competent
management team; (v) motivating executive personnel by means of performance-related incentives to achieve longer-range performance goals; (vi) providing incentive compensation opportunities which are competitive with those of other major
corporations; (vii) enabling Company employees and executive personnel to participate in the long-term growth and financial success of the Company through increased stock ownership and (viii) serving as a mechanism to attract, retain and
properly compensate outside directors. Where the grant of shares of stock under this Plan is restricted or rendered impracticable by foreign local laws and/or regulations, the foregoing purposes will be promoted through some alternative arrangement
(or in some cases cash equivalents) as applicable. 
 1.2 Certain Definitions. In addition to the defined terms
set forth elsewhere in this Plan, the terms set forth below, shall, when capitalized, have the following respective meanings. 
 “Agreement” shall mean the written agreement evidencing an award hereunder between the Company and the recipient of such award. 
 “Board” shall mean the Board of Directors of the Company. 
 “Bonus Stock” shall mean shares of Common Stock that are not subject to a Restriction Period or Performance
Measures. 
 “Cause” shall mean the willful and continued failure to substantially
perform the duties assigned by the Company (other than a failure resulting from the optionee’s Disability), the willful engaging in conduct which is demonstrably injurious to the Company or any Subsidiary, monetarily or otherwise, including
conduct that, in the reasonable judgment of the Committee, no longer conforms to the standard of the Company’s employees or executives, any act of dishonesty, commission of a felony, or a significant violation of any statutory or common law
duty of loyalty to the Company. 
 “Change in Control” shall have the meaning set forth
in Section 6.8(b). 
 “Code” shall mean the Internal Revenue Code of 1986, as
amended. 
 “Committee” shall mean the Compensation Committee of the Board or a
subcommittee thereof, or any other committee designated by the Board to administer this Plan, consisting of two or more members of the Board, each of whom shall be (i) a “Non-Employee Director” within the meaning of Rule 16b-3 under
the Exchange Act, (ii) an “outside director” within the meaning of Section 162(m) of the Code, and (iii) an “Independent Director” within the meaning of the rules of the New York Stock Exchange. 
 “Common Stock” shall mean the new common stock, $.01 par value, of the Company. 
 “Disability” shall mean the inability of the holder of an award to perform substantially such
holder’s duties and responsibilities for a continuous period of at least six months, as determined solely by the Committee. To the extent that Code Section 409A is applicable to a particular award, the term “Disability” shall
have the meaning as defined under that Section. 
  

 1 

 “Exchange Act” shall mean the Securities Exchange
Act of 1934, as amended. 
 “Fair Market Value” shall mean the closing transaction price
of a share of Common Stock as reported on the New York Stock Exchange on the date as of which such value is being determined or, if the Common Stock is not listed on the New York Stock Exchange, the closing transaction price of a share of Common
Stock on the principal national stock exchange on which the Common Stock is traded on the date as of which such value is being determined or, if there shall be no reported transactions for such date, on the next preceding date for which transactions
were reported; provided further, that Fair Market Value may be determined by the Committee by whatever other means or method as the Committee, in the good faith exercise of its discretion, shall at such time deem appropriate. Notwithstanding the
foregoing, for any purposes under this Plan including for Plan administrative purposes, the Committee may, in its discretion, apply any other definition of Fair Market Value which is reasonable and consistent with applicable tax, accounting and
other rules. 
 “Free-Standing SAR” shall mean an SAR which is not granted in tandem
with, or by reference to, an option, which entitles the holder thereof to receive, upon exercise, shares of Common Stock (which may be Restricted Stock), cash or a combination thereof, as set forth in the Agreement, with an aggregate value equal to
the excess of the Fair Market Value of one share of Common Stock on the date of exercise over the base price of such SAR, multiplied by the number of such SARs which are exercised. 
 “Incentive Stock Option” shall mean an option to purchase shares of Common Stock which meets the
requirements of Section 422 of the Code, or any successor provision, and which is intended by the Committee to constitute an Incentive Stock Option. 
 “Non-Employee Director” shall mean any director of the Company who is not an officer or employee of the Company or any Subsidiary. 
 “Non-Qualified Stock Option” shall mean an option to purchase shares of Common Stock that is not an
Incentive Stock Option. 
 “Participant” shall mean an individual who has been granted
an Incentive Stock Option, a Non-Qualified Stock Option, an SAR, a Bonus Stock Award, Performance Share Award, Restricted Stock Award or Restricted Stock Unit Award. 
 “Performance Measures” shall mean the criteria and objectives, established by the Committee, which
shall be satisfied or met (i) as a condition to the exercisability of all or a portion of an option or SAR, (ii) as a condition to the grant of a Stock Award or (iii) during the applicable Restriction Period or Performance Period as a
condition to the holder’s receipt of Common Stock subject to a Restricted Stock Award or a Performance Share Award and/or of payment with respect to such award. The Committee may amend or adjust the Performance Measures or other terms and
conditions of an outstanding award in recognition of unusual or nonrecurring events affecting the Company or its financial statements or changes in law or accounting, but only to the extent such adjustment would not cause any portion of the award,
upon payment, or the option, upon exercise, to be nondeductible pursuant to Section 162(m) of the Code. Such criteria and objectives may include one or more of the following: total stockholder return (based on the change in the price of a share
of the Company’s Common Stock and dividends paid); brand recognition or acceptance; cost savings or waste elimination; earnings before interest, taxes and amortization (“EBITA”); also EBIT, EBITDA, OBIT, or OBITDA; earnings per share;
income; operating income; market share or market segment share; net income; new product innovation; operating profit or net operating profit; operating margins or profit margins; profits or gross profits; product cost reductions; product release
schedules; return on stockholder’s equity; return on assets; return on capital employed; return on invested capital; return on operating revenue; revenue or revenue growth; sales or segment sales; share price performance; strategic corporate
objectives (including but not limited to: increase in revenue with certain customers, customer groups, or customer types; revenues, synergies or savings related to corporate transactions; safety performance; sustainability or environmental
performance); economic value added; and cash flows (including, but not limited to: operating cash flow, free cash flow, cash flow return on equity and cash flow 

  

 2 

 
return on investment); any combination of the foregoing performance measures; or any other performance measure as selected by the Committee which is intended
to meet the requirements for performance based compensation under Section 162(m) of the Code. If the Committee desires that compensation payable pursuant to any award subject to Performance Measures be “qualified performance-based
compensation” within the meaning of Section 162(m) of the Code, the Performance Measures (i) shall be established by the Committee no later than the end of the first quarter of the Performance Period or Restriction Period, as
applicable (or such other time designated by the Internal Revenue Service) and (ii) shall satisfy all other applicable requirements imposed under Treasury Regulations promulgated under Section 162(m) of the Code, including the requirement
that such Performance Measures be stated in terms of an objective formula or standard. 
 “Performance
Period” shall mean any period designated by the Committee during which the Performance Measures applicable to a Performance Share Award shall be measured. 
 “Performance Share” shall mean a right, contingent upon the attainment of specified Performance
Measures within a specified Performance Period, to receive one share of Common Stock, which may be Restricted Stock, or in lieu of all or a portion thereof, at the Committee’s discretion, the Fair Market Value of such Performance Share in cash.

 “Performance Share Award” shall mean an award of Performance Shares under this Plan.

 “Permanent and Total Disability” shall have the meaning set forth in
Section 22(e) (3) of the Code or any successor thereto. 
 “Restricted Stock”
shall mean shares of Common Stock that are subject to a Restriction Period. 
 “Restricted Stock
Unit” shall mean the right to receive one share of Common Stock which shall be contingent upon the expiration of a specified Restriction Period and subject to such additional restrictions as may be contained in the Agreement
relating thereto. 
 “Restriction Period” shall mean any period designated by the
Committee during which (i) the Common Stock subject to a Restricted Stock Award may not be sold, transferred, assigned, pledged, hypothecated or otherwise encumbered or disposed of, except as provided in this Plan or the Agreement relating to
such award or (ii) the conditions to vesting applicable to a Restricted Stock Unit Award shall remain in effect. 
 “SAR” shall mean a stock appreciation right which may be a Free Standing SAR or a Tandem SAR. 
 “Stock Award” shall mean a Restricted Stock Award, a Restricted Stock Unit Award, or a Bonus Stock Award. 
 “Tandem SAR” shall mean an SAR which is granted in tandem with, or by reference to, an option
(including a Non-Qualified Stock Option granted prior to the date of grant of the SAR), which entitles the holder thereof to receive, upon exercise of such SAR and surrender for cancellation of all or a portion of such option, shares of Common Stock
(which may be Restricted Stock), cash or a combination thereof with an aggregate value equal to the excess of the Fair Market Value of one share of Common Stock on the date of exercise over the base price of such SAR, multiplied by the number of
shares of Common Stock subject to such option, or portion thereof, which is surrendered. 
 1.3 Administration.
This Plan shall be administered by the Committee. The Committee shall have the authority to determine eligibility for awards hereunder and to determine the form, amount and timing of each award to such persons and, if applicable, the number of
shares of Common Stock, and the number of Performance Shares subject to such an award, the exercise price associated with the award, the time and conditions of exercise or settlement of the award and all other terms and conditions of the award,
including, without limitation, the form of the Agreement evidencing the award. The Committee may, in its sole discretion and for any reason at any time, subject to the requirements imposed under Section 162(m) of the Code and regulations
promulgated thereunder in the case of an award intended to be qualified performance-based 

  

 3 

 
compensation, take action such that (i) any or all outstanding options, stock awards, and/or SARs shall become exercisable in part or in full,
(ii) all or a portion of the Restriction Period applicable to any outstanding Restricted Stock Award shall lapse, (iii) all or a portion of the Performance Period applicable to any outstanding Performance Share Award shall lapse,
(iv) the Performance Measures applicable to any outstanding Restricted Stock Award (if any) and to any outstanding Performance Share Award shall be deemed to be satisfied at the maximum or any other level. 
 The Committee shall, subject to the terms of this Plan, interpret this Plan and the application thereof, establish rules and regulations it deems
necessary or desirable for the administration of this Plan and may impose, incidental to the grant of an award, conditions with respect to the award, such as limiting competitive employment or other activities. All such interpretations, rules,
regulations and conditions shall be final, binding and conclusive. 
 The Committee shall keep minutes of its meetings and of action taken by
it without a meeting. A majority of the Committee shall constitute a quorum. The acts of the Committee shall be either (i) acts of a majority of the members of the Committee present at any meeting at which a quorum is present or (ii) acts
approved in writing by all of the members of the Committee without a meeting. 
 Notwithstanding anything in the Plan to the contrary, in
accordance with Section 157 of the Delaware General Corporation Law, the Committee may, by resolution, authorize one or more executive officers of the Company to do one or both of the following: (i) designate non-director and non-executive
officer employees of the Company or any of its Subsidiaries to be recipients of rights or options entitling the holder thereof to purchase from the Company shares of its capital stock of any class or other awards hereunder; and (ii) determine
the number of such rights or options, or awards to be received by such non-director and non-executive officer employees; provided, however, that the resolution so authorizing such executive officer or officers shall specify the total number of
rights or options, or awards such executive officer or officers may so award. The Committee may not authorize an executive officer to designate himself or herself or any director or other executive officer of the Company to be a recipient of any
such rights, options, or awards. 
 Notwithstanding anything in the Plan to the contrary, to the extent an award granted hereunder would be
subject to the requirements of Section 409A of the Code and the regulations thereunder, then the Agreement for such award and the Plan shall be construed and administered so as the award complies with Section 409A of the Code and the
regulations thereunder. 
 Awards may be granted to Participants in jurisdictions outside the United States. To the extent necessary or
advisable to comply with applicable local laws while concurrently aiming to achieve the purposes of the Plan it may be determined by the Committee that the terms and conditions applicable to those awards granted to Participants outside the United
States are different from those under the Plan. 
 1.4 Eligibility. Participants in this Plan shall consist of
such directors, officers, and employees of the Company and its Subsidiaries, Affiliates or Joint Ventures from time to time, and any other entity designated by the Board or the Committee (individually a “Subsidiary” and collectively the
“Subsidiaries”) as the Committee, in its sole discretion, may select from time to time. For purposes of this Plan, reference to employment by the Company shall also mean employment by a Subsidiary, Affiliate or Joint Venture. 

1.5 Shares Available. Subject to adjustment as provided in Section 6.7, 12,600,000 shares of Common Stock shall be
available under this Plan, reduced by the sum of the aggregate number of shares of Common Stock which become subject to outstanding options, including Directors Options, outstanding Free-Standing SARs, outstanding Stock Awards and outstanding
Performance Shares. To the extent that shares of Common Stock subject to an outstanding option (except to the extent shares of Common Stock are issued or delivered by the Company in connection with the exercise of a Tandem SAR), Free-Standing SAR,
Stock Award or Performance Share are not issued or delivered by reason of the expiration, termination, cancellation or forfeiture of such 

  

 4 

 
award, then such shares of Common Stock shall again be available under this Plan. Notwithstanding any other provision of the Plan to the contrary, any and
all of the shares available under this paragraph shall be available for any or all types of awards, including full value stock awards, which are available under the terms of the Plan. 
 Shares of Common Stock shall be made available from authorized and unissued shares of Common Stock, or authorized and issued shares of Common Stock
reacquired and held as treasury shares or otherwise or a combination thereof. 
 To the extent required by Section 162(m) of the Code
and the rules and regulations thereunder, the maximum number of shares of Common Stock with respect to which options, SARs, Stock Awards or Performance Share Awards or a combination thereof may be granted during any calendar year to any person shall
be 300,000, subject to adjustment as provided in Section 6.7. 
 For purposes of grants of Incentive Stock Options under this Plan, the
maximum number of shares available for such grant(s) shall be no more than 2,000,000 shares. 
 II. STOCK OPTIONS AND STOCK APPRECIATION
RIGHTS 
 2.1 Stock Options. The Committee may, in its discretion, grant Incentive Stock Options or
Non-Qualified Stock Options to such eligible persons under Section 1.4 as may be selected by the Committee. 
 Options shall be subject
to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable: 
 (a) Number of Shares and Purchase Price. The number of shares and the purchase price per share of Common Stock subject to an option
shall be determined by the Committee, provided, however, that the purchase price per share of Common Stock shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date of grant of such option and provided further, that
if an Incentive Stock Option shall be granted to any person who, at the time such option is granted, owns capital stock possessing more than ten percent of the total combined voting power of all classes of capital stock of the Company (or of any
parent or subsidiary as defined in Section 424 of the Code) (a “Ten Percent Holder”), the purchase price per share of Common Stock shall be the price (currently 110% of Fair Market Value) required by the Code in order to
constitute an Incentive Stock Option. 
 (b) Option Period and Exercisability. Each option, by its terms, shall require
the Participant to remain in the continuous employ of the Company for at least one year following the date of grant of the option before any part of the option shall be exercisable, except in the case of a Change in Control. The period during which
an option may be exercised shall be determined by the Committee; provided, however, that no Incentive Stock Option nor Non-Qualified Stock Option shall be exercised later than ten years after its date of grant; provided further, that if an Incentive
Stock Option shall be granted to a Ten Percent Holder, such option shall not be exercised later than five years after its date of grant. Once determined and stated in an Agreement with respect to an option, the period during which an option can be
exercised shall not be further extended. The Committee may, in its discretion, establish Performance Measures which shall be satisfied or met as a condition to the grant of an option or to the exercisability of all or a portion of an option. The
Committee shall determine whether an option shall become exercisable in cumulative or non-cumulative installments and in part or in full at any time. An exercisable option, or portion thereof, may be exercised only for whole shares of Common Stock.

 (c) Method of Exercise. An option may be exercised (i) by giving written notice to the Company specifying the
number of whole shares of Common Stock to be purchased and accompanied by payment therefor in full (or arrangement made for such payment to the Company’s satisfaction) either (A) by the delivery of cash in the amount of the aggregate
purchase price payable by reason of such exercise, (B) for 

  

 5 

 
employees other than Canadian employees, by delivery (either actual delivery or by attestation procedures established by the Company) of previously acquired
shares of Common Stock that have an aggregate Fair Market Value, determined as of the date of exercise, equal to the aggregate purchase price payable by reason of such exercise (C) by the delivery of cash in the amount of the aggregate purchase
price payable by reason of such exercise by a broker-dealer acceptable to the Company to whom the optionee has submitted an irrevocable notice of exercise, or (D) a combination of (A) and (B), in each case to the extent set forth in the
Agreement relating to the option, (ii) if applicable, by surrendering to the Company any Tandem SARs which are cancelled by reason of the exercise of the option and (iii) by executing such documents as the Company may reasonably request.
Any fraction of a share of Common Stock which would be required to pay such purchase price shall be disregarded and the remaining amount due shall be paid in cash by the optionee. No shares of Common Stock shall be issued and no certificate
representing Common Stock shall be delivered until the full purchase price therefore has been paid (or arrangement made for such payment to the Company’s satisfaction). 
 Notwithstanding the foregoing, permitted exercise methods may be limited by the terms of the individual Award Agreement. 
 2.2 Stock Appreciation Rights. The Committee may, in its discretion, grant SARs to such eligible persons under
Section 1.4 as may be selected by the Committee. The Agreement relating to an SAR shall specify whether the SAR is a Tandem SAR or a Free-Standing SAR. 
 SARs shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable: 
 (a) Number of SARs and Base Price. The number of SARs subject to an award shall be determined by the Committee. Any Tandem SAR
related to an Incentive Stock Option shall be granted at the same time that such Incentive Stock Option is granted. The base price of a Tandem SAR shall be the purchase price per share of Common Stock of the related option. The base price of a
Free-Standing SAR shall be determined by the Committee; provided, however, that such base price shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date of grant of such SAR. 
 (b) Exercise Period and Exercisability. Each SAR, by its terms, shall require the Participant to remain in the continuous employ of
the Company for at least one year following the date of grant of the SAR before any part of the SAR shall be exercisable, except in the case of a Change in Control. The Agreement relating to an award of SARs shall specify whether such award may be
settled in shares of Common Stock (including shares of Restricted Stock) or cash or a combination thereof, provided, however, that cash settled SARs may only be granted to persons not subject to United States income tax laws, including
Section 409A of the Code and the rules and regulations promulgated thereunder. The period for the exercise of an SAR shall be determined by the Committee; provided, however, that no SAR may be exercised later than 10 years after its date of
grant; provided further, that no Tandem SAR shall be exercised later than the expiration, cancellation, forfeiture or other termination of the related option. Once determined and stated in an Agreement with respect to an SAR, the period during which
an SAR can be exercised shall not be further extended. The Committee may, in its discretion, establish Performance Measures which shall be satisfied or met as a condition to the grant of an SAR or to the exercisability of all or a portion of an SAR.
The Committee shall determine whether an SAR may be exercised in cumulative or non-cumulative installments and in part or in full at any time. An exercisable SAR, or portion thereof, may be exercised, in the case of a Tandem SAR, only with respect
to whole shares of Common Stock and, in the case of a Free Standing SAR, only with respect to a whole number of SARs. If an SAR is exercised for shares of Restricted Stock, a certificate or certificates representing such Restricted Stock shall be
issued in accordance with Section 3.2(c), or such shares shall be transferred to the holder in book entry form with restrictions on the Shares duly noted, and the holder of such Restricted Stock shall have such rights of a stockholder of the
Company as determined pursuant to Section 3.2(d). Prior to the exercise of an SAR for shares of Common Stock, including Restricted Stock, the holder of such SAR shall have no rights as a stockholder of the Company with respect to the shares of
Common Stock subject to such SAR. 
  

 6 

 (c) Method of Exercise. A Tandem SAR may be exercised (i) by giving written
notice to the Company specifying the number of whole SARs which are being exercised, (ii) by surrendering to the Company any options which are cancelled by reason of the exercise of the Tandem SAR and (iii) by executing such documents as
the Company may reasonably request. A Free-Standing SAR may be exercised (i) by giving written notice to the Company specifying the whole number of SARs which are being exercised and (ii) by executing such documents as the Company may
reasonably request. 
 2.3 Termination of Employment or Service. (a) Non-Qualified Stock Options and
SARs. All of the terms relating to the exercise period or to the vesting, in whole or in part, or forfeiture and cancellation of such option or SAR award upon a termination of employment or service with the Company of the holder, whether by
reason of disability, retirement, death or any other reason, shall be determined by the Committee and as set forth in the Agreement. Notwithstanding the foregoing, age and service requirements set forth in any individual Award Agreement will be
inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age Discrimination Directive. 
 (b) Incentive Stock Options. All of the terms relating to the exercise period or to the vesting, in whole or in part, or forfeiture and cancellation of such Incentive Stock Option award upon a termination of employment or service
with the Company of the holder, whether by reason of disability, retirement, death or any other reason, shall be determined by the Committee and as set forth in the Agreement. Notwithstanding the foregoing, age and service requirements set forth in
any individual Award Agreement will be inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age Discrimination Directive. 
 (c) Continuation of Service as a Non-Employee Director. Unless otherwise set forth in the Agreement, a holder’s employment
with the Company will not be deemed to have terminated for purposes of this Section 2.3 if the holder continues to provide services to the Company as a Non-Employee Director. 
 2.4 No Repricing. Notwithstanding anything in this Plan to the contrary and subject to Section 6.7, without the approval
of the stockholders of the Company the Committee will not amend or replace any previously granted option or SAR in a transaction that constitutes a “repricing,” as such term is used in Section 303A.08 of the Listed Company Manual of
the New York Stock Exchange. Further, except in connection with a corporate transaction involving the company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger,
consolidation, split-up, spin-off, combination, or exchange of shares), the terms of outstanding awards may not be amended to reduce the exercise price of outstanding Incentive Stock Options, Non-Qualified Stock Options or SARs or cancel outstanding
Incentive Stock Options, Non-Qualified Stock Options or SARs in exchange for cash, other awards or Incentive Stock Options, Non-Qualified Stock Options or SARs with an exercise price that is less than the exercise price of the original Incentive
Stock Options, Non-Qualified Stock Options or SARs without stockholder approval. 
 III. STOCK AWARDS 
 3.1 Stock Awards. The Committee may, in its discretion, grant Stock Awards to such eligible persons under Section 1.4 as
may be selected by the Committee. The Agreement relating to the Stock Award shall specify whether the Stock Award is a Restricted Stock Award, a Restricted Stock Unit Award, or Bonus Stock Award. 
 3.2 Terms of Stock Awards. Stock Awards shall be subject to the following terms and conditions and shall contain such
additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable. 
 (a)
Number of Shares and Other Terms. The number of shares of Common Stock subject to a Restricted Stock Award, Restricted Stock Unit Award, or Bonus Stock Award and the Performance Measures (if any) and Restriction Period applicable to a
Restricted Stock Award or Restricted Stock Unit Award shall be determined by the Committee and set forth in the individual award Agreement. 
  

 7 

 (b) Vesting and Forfeiture. The Agreement relating to a Restricted Stock Award or
Restricted Stock Unit Award shall provide, in the manner determined by the Committee in its discretion, and subject to the provisions of this Plan, for the vesting, in whole or in part, of the shares of Common Stock subject to such award, in the
case of a Restricted Stock Award, or the vesting of the Restricted Stock Unit Award itself, in the case of Restricted Stock Unit Award, (i) if specified Performance Measures are satisfied or met during the specified Restriction Period or
(ii) if the holder of such award remains continuously in the employment of or service to the Company during the specified Restriction Period, and for the forfeiture of the shares of Common Stock subject to such award in the case of a Restricted
Stock Award, or the forfeiture of the Restricted Stock Unit Award itself, in the case of a Restricted Stock Unit Award, (x) if specified Performance Measures are not satisfied or met during the specified Performance Period or (y) if the
holder of such award does not remain continuously in the employment of or service to the Company during the specified Restriction Period. 
 Any equity-based awards other than ISOs, NQSOs, or SARs which vest on the basis of the Participant’s continued employment with the passage of time and/or provision of service to the Company shall not provide for
vesting which is any more rapid than annual pro rata vesting over a three (3) year period and any equity-based awards other than ISOs, NQSOs, or SARs which vest upon the attainment of performance goals shall provide for a performance period of
at least twelve (12) months. Notwithstanding the foregoing, the Committee may permit acceleration of vesting of any such equity-based awards other than ISOs, NQSOs, or SARs in the event of the Participant’s death, disability, or
retirement, or a Change of Control. 
 Bonus Stock Awards shall not be subject to any Performance Measures or Restriction
Periods. 
 (c) Stock Issuance. During the Restriction Period, the shares of Restricted Stock shall be held by a
custodian in book entry form with restrictions on such shares duly noted or, alternatively, a certificate or certificates representing a Restricted Stock Award shall be registered in the holder’s name and may bear a legend, in addition to any
legend which may be required pursuant to Section 6.6, indicating that the ownership of the shares of Common Stock represented by such certificate is subject to the restrictions, terms and conditions of this Plan and the Agreement relating to
the Restricted Stock Award. All such certificates shall be deposited with the Company, together with stock powers or other instruments of assignment (including a power of attorney), each endorsed in blank with a guarantee of signature if deemed
necessary or appropriate, which would permit transfer to the Company of all or a portion of the shares of Common Stock subject to the Restricted Stock Award in the event such award is forfeited in whole or in part. Upon termination of any applicable
Restriction Period (and the satisfaction or attainment of applicable Performance Measures), subject to the Company’s right to require payment of any taxes in accordance with Section 6.5, the restrictions shall be removed from the requisite
number of any shares of Common Stock that are held in book entry form, and all certificates evidencing ownership of the requisite number of shares of Common Stock shall be delivered to the holder of such award. 
 (d) Rights with Respect to Restricted Stock Awards. Unless otherwise set forth in the Agreement relating to a Restricted Stock
Award, and subject to the terms and conditions of a Restricted Stock Award, the holder of such award shall have all rights as a stockholder of the Company, including, but not limited to, voting rights, the right to receive dividends and the right to
participate in any capital adjustment applicable to all holders of Common Stock; provided, however, that a distribution with respect to shares of Common Stock, other than a regular cash dividend, shall be deposited with the Company and shall be
subject to the same restrictions as the shares of Common Stock with respect to which such distribution was made. 
 (e)
Rights and Provisions Applicable to Restricted Stock Unit Awards. The Agreement relating to a Restricted Stock Unit Award shall specify whether the holder thereof shall be entitled to receive, on a current or deferred basis, dividend
equivalents, or the deemed reinvestment of, any deferred dividend equivalents, with respect to the number of shares of Common Stock subject to such award. Prior to the settlement of a Restricted Stock Unit Award, the holder thereof shall not have
any rights as a stockholder of the Company with respect to the shares of Common Stock subject to such award, except to the extent that 

  

 8 

 
the Committee, in its sole discretion, may grant dividend equivalents on Restricted Stock Unit Awards as provided above. No shares of Common Stock and no
certificates representing shares of Common Stock that are the subject to a Restricted Stock Unit Award shall be issued upon the grant of a Restricted Stock Unit Award. Instead, shares of Common Stock subject to Restricted Stock Unit Awards and the
certificates representing such shares of Common Stock shall only be distributed at the time of settlement of such Restricted Stock Unit Awards in accordance with the terms and conditions of this Plan and the Agreement relating to such Restricted
Stock Unit Award. 
 3.3 Termination of Employment or Service. All of the terms relating to the satisfaction of
Performance Measures and the termination of the Restriction Period or Performance Period relating to a Stock Award, or any vesting, in whole or in part, or forfeiture and cancellation of such award upon a termination of employment or service with
the Company of the holder of such award, whether by reason of disability, retirement, death or any other reason, shall be determined by the Committee and as set forth in the Agreement. Notwithstanding the foregoing, age and service requirements set
forth in any individual Award Agreement will be inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age Discrimination Directive. 
 IV. PERFORMANCE SHARE AWARDS 
 4.1 Performance Share
Awards. The Committee may, in its discretion, grant Performance Share Awards to such eligible persons under Section 1.4 as may be selected by the Committee. 
 4.2 Terms of Performance Share Awards. Performance Share Awards shall be subject to the following terms and conditions and
shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable. 
 (a) Number of Performance Shares and Performance Measures. The number of Performance Shares subject to any award and the Performance Measures and Performance Period applicable to such award shall be determined
by the Committee. 
 (b) Vesting and Forfeiture. The Agreement relating to a Performance Share Award shall provide, in
the manner determined by the Committee, in its discretion, and subject to the provisions of this Plan, for the vesting of such award, if specified Performance Measures are satisfied or met during the specified Performance Period, and for the
forfeiture of such award, if specified Performance Measures are not satisfied or met during the specified Performance Period. 
 (c) Settlement of Vested Performance Share Awards. The Agreement relating to a Performance Share Award (i) shall specify whether such award may be settled in shares of Common Stock (including shares of Restricted Stock) or cash
or a combination thereof and (ii) may specify whether the holder thereof shall be entitled to receive, on a current or deferred basis, dividend equivalents, and, if determined by the Committee, interest on or the deemed reinvestment of any
deferred dividend equivalents, with respect to the number of shares of Common Stock subject to such award. If a Performance Share Award is settled in shares of Restricted Stock, such shares of Restricted Stock shall be issued to the holder in book
entry form or a certificate or certificates representing such Restricted Stock shall be issued in accordance with Section 3.2(c) and the holder of such Restricted Stock shall have such rights of a stockholder of the Company as determined
pursuant to Section 3.2(d). Prior to the settlement of a Performance Share Award in shares of Common Stock, including Restricted Stock, the holder of such award shall have no rights as a stockholder of the Company with respect to the shares of
Common Stock subject to such award and shall have rights as a stockholder of the Company in accordance with Section 6.10. Notwithstanding any other provision of the Plan to the contrary, payments of cash, shares of Common Stock, or any
combination thereof to any Participant in respect of the settlement of any single Performance Share Award for any Performance Period shall not exceed seven million dollars, with respect to the cash payment for such award, and shall not exceed
300,000 shares of Common Stock, with respect to the Common Stock payment for such award. 
  

 9 

 4.3 Termination of Employment or Service. All of the terms relating to the
satisfaction of Performance Measures and the termination of the Performance Period relating to a Performance Unit Award, or any forfeiture and cancellation of such award upon a termination of employment or service with the Company of the holder of
such award, whether by reason of disability, retirement, death or any other reason, shall be determined by the Committee 
 V. PROVISIONS
RELATING TO NON-EMPLOYEE DIRECTORS 
 5.1 Eligibility. Each Non-Employee Director is eligible to receive
awards consisting of restricted stock and/or grants of options to purchase shares of Common Stock in accordance with this Article V and pursuant to terms and conditions as established by the Committee as set forth in an individual agreement
regarding each such award. All options granted under this Article V shall constitute Non-Qualified Stock Options. 
 5.2
Grants of Stock Options and/or Awards of Restricted Stock: 
 (a) Grant upon Initial Election.
Current Non-Employee Directors as of October 30, 2006, and future Non-Employee Directors upon first election to the Board, shall be eligible for an award under this Plan, in such amount and form, and with such terms and conditions as determined
by the Committee. 
 (b) Restrictions, Exercise Period and Exercisability. For each award granted under this
Section 5.2, vesting and other terms, conditions and requirements, if any, shall be as determined by the Committee at the time of grant and as reflected in the Agreement, or as otherwise set forth in Section 5.5 and/or 5.6 below. Options
granted under this Section 5.2 shall expire 10 years after its date of grant. An exercisable option, or portion thereof, may be exercised in whole or in part only with respect to whole shares of Common Stock. Options granted under this
Section 5.2 shall be exercisable in accordance with Section 2.1(c). 
 5.3 Termination of Service. 

 (a) General. All of the terms relating to the exercise or to the vesting, in whole or in part, or forfeiture and
cancellation of such an option granted under Section 5.2 upon the holder ceasing to be a director of the Company, whether by reason of disability, retirement, death or any other reason, shall be determined by the Committee and as set forth in
the individual award Agreement. Notwithstanding the foregoing, age and service requirements set forth in any individual Award Agreement will be inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age
Discrimination Directive. 
 (b) Death Following Termination of Directorship. If the holder of an option granted under
Section 5.2 dies during the period set forth in Section 5.3(a) following such holder’s ceasing to be a director of the Company by reason of disability, retirement, or any other reason, each such option held by such holder shall be
exercisable only to the extent that such option is exercisable on the date of the holder’s death and may thereafter be exercised by such holder’s executor, administrator, legal representative, beneficiary or similar person until and
including the earliest to occur of the (i) a date which is a specific period, as set forth in the individual award agreement, after the date of death, if any such period is specified in the Agreement and (ii) the expiration date of the
term of such option. 
 (c) Continuation of Service as an Employee. A holder’s directorship will not be deemed to
have terminated for purposes of this Section 5.3 if the holder continues to provide services to the Company as an employee of the Company. 
 5.4 Other Plan Non-Employee Director Equity Awards. 
 (a) In addition to any award
received under Section 5.2 of this Plan as set forth above, each Non-Employee Director shall be eligible for, and may from time to time be granted, an award under the Plan consisting of restricted stock and/or a grant of options to purchase
shares of Common Stock in such amount as determined by the Committee. Each such award to a Non-Employee Director shall be awarded in accordance with this Article V and any additional terms and conditions made applicable by the Committee or by an
individual agreement. 
  

 10 

 (b) Each Non-Employee Director may also from time to time elect, in accordance with
procedures to be specified by the Committee and subject to approval of the Committee, to receive in lieu of all or part of a specified percentage of the cash retainer and any meeting fees that would otherwise be payable to such Non-Employee Director
either (i) Restricted Stock or Restricted Stock Units under this Plan, if available, having the terms described in Section 5.5 (“Directors Restricted Stock”), using the Fair Market Value of Common Stock as of the election
date, equal to the amount of the forgone retainer and meeting fees; or (ii) options under this Plan, if available, having the terms described in Section 5.6 (“Directors Options”) to purchase shares of Common Stock, using
the Fair Market Value of Common Stock as of the election date, equal to the amount of the forgone retainer and meeting fees. Any election under this paragraph 5.4 shall be made under an appropriate election form and appropriate individual award
agreement or agreements and shall have terms and conditions set forth in such agreement and as approved by the Committee. 
 (c) In addition to the foregoing, any Award to Non-Employee Directors of Restricted Stock, Restricted Stock Units or Options under this Plan which are not immediately vested may be deferred at vesting through an appropriate deferral
election by the Director. 
 (d) Any election made under this Section must be made prior to the year in which such cash
retainer and meeting fees are earned for purposes of elections under paragraph (b) above, or prior to the period of service applicable to the vesting of such award under paragraph (c) above in accordance with requirements under
Section 409A of the Code, and any elections shall be deferred with such terms and conditions as specified in such election. 
 5.5
Directors Restricted Stock. Shares of Directors Restricted Stock shall be subject to a Restriction Period commencing on the date of grant of such award and terminating on the specified anniversary date of the date of grant
of such award (as determined by the Committee in its discretion and as set forth in the Agreement), shall vest if the holder of such award remains continuously in the service of the Company as a Non-Employee Director during the Restriction Period
and shall be forfeited if the holder of such award does not remain continuously in the service of the Company as a Non-Employee Director or employee of the Company during the Restriction Period. A certificate or certificates representing Directors
Restricted Stock shall be issued in accordance with Section 3.2(c) and the holder of such award shall have such rights of a stockholder of the Company as determined pursuant to Section 3.2(d). 
 Notwithstanding the foregoing paragraph, if the service to the Company as a Non-Employee Director or employee of the Company of the holder of Directors
Restricted Stock terminates or ceases to be a director or employee whether by reason of disability, retirement, death or any other reason, the termination of the Restriction Period shall be determined by the Committee as set forth in the individual
award Agreement. Notwithstanding the foregoing, age and service requirements set forth in any individual Award Agreement will be inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age Discrimination
Directive. 
 5.6 Director’s Options. Each Director’s Option shall be subject to the following terms
and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable: 
 (a) Exercise Period and Exercisability. For each Director’s Option, such option shall be exercisable, and vesting and other requirements shall apply, if any, as shall be determined by the Committee at the time of
grant. Each Director’s Option shall expire 10 years after its date of grant. 
 (b) Purchase Price. The purchase price
for the shares of Common Stock subject to any Director’s Option shall be equal to 100% of the Fair Market Value of a share of Common Stock on the date of grant of such Director’s Option. An exercisable Director’s Option, or portion
thereof, may be exercised in whole or in part only with respect to whole shares of Common Stock. Director’s Options shall be exercisable in accordance with Section 2.1(c). 
  

 11 

 (c) Termination of Service. If the holder of a Director’s Option ceases to be a
director of the Company by reason of whether by reason of disability, retirement, death or any other reason, the exercise of such option shall be determined by the Committee and as set forth in the individual award Agreement. Notwithstanding the
foregoing, age and service requirements set forth in any individual Award Agreement will be inapplicable in jurisdictions where they are in conflict with implementation of the European Union Age Discrimination Directive. 
 If the holder of a Director’s Option dies during the period set forth in the first paragraph of this Section 5.6(c) following
such holder’s ceasing to be a director of the Company by reason of disability, retirement, or any other reason, each such Director’s Option held by such holder shall be exercisable only to the extent that such option is exercisable on the
date of the holder’s death and may thereafter be exercised by such holder’s executor, administrator, legal representative, beneficiary or similar person until and including the earliest to occur of the (i) a date which is a specific
period, as set forth in the individual award agreement, after the date of death, if any such period is specified in the Agreement and (ii) the expiration date of the term of such option. 
 A holder’s directorship will not be deemed to have terminated for purposes of this Section 5.6 if the holder continues to
provide services to the Company as an employee of the Company. 
 VI. GENERAL 
 6.1 Effective Date and Term of Plan. This Plan, as amended and restated, has been approved by the stockholders of the Company
and is effective as of December 6, 2007. This Plan shall terminate on December 17, 2017, unless terminated earlier by the Board. Termination of this Plan shall not affect the terms or conditions of any award granted prior to termination.

 6.2 Amendments. The Committee may amend this Plan as it shall deem advisable, subject to any requirement of
stockholder approval required by applicable law, rule or regulation, including Section 162(m) and Section 422 of the Code; provided, however, that no amendment shall be made without stockholder approval if such amendment would
(a) increase the maximum number of shares of Common Stock available under this Plan (subject to Section 6.7), (b) effect any change inconsistent with Section 422 of the Code, (c) extend the term of this Plan or
(d) reduce the minimum purchase price of a share of Common Stock subject to an option. No amendment may impair the rights of a holder of an outstanding award without the consent of such holder. 
 Awards may be granted to Participants in jurisdictions outside the United States. To the extent necessary or advisable to comply with applicable local
laws while concurrently aiming to achieve the purposes of the Plan, it may be determined by the Committee that the terms and conditions applicable to those awards granted to Participants outside the United States are different from those under the
Plan. 
 6.3 Agreement. Each award under this Plan shall be evidenced by an Agreement setting forth the terms and
conditions applicable to such award. No award shall be valid until an Agreement is executed by the Company and the recipient of such award and, upon execution by each party and delivery of the Agreement to the Company, such award shall be effective
as of the effective date set forth in the Agreement. 
 6.4 Non-Transferability of Awards. Unless otherwise
specified in the Agreement relating to an award, no award shall be transferable other than by will, the laws of descent and distribution or pursuant to beneficiary designation procedures approved by the Company. Except to the extent permitted by the
foregoing sentence or the Agreement relating to an award, each award may be exercised or settled during the holder’s lifetime only by the holder or the holder’s legal representative or similar person. Except to the extent permitted by the
second preceding sentence or the Agreement relating to an award, no award may be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution,
attachment or similar process. Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of any such award, such award and all rights thereunder shall immediately become null and void. 
  

 12 

 6.5 Tax Withholding. The Company shall have the right to require, prior to
the issuance or delivery of any shares of Common Stock or the payment of any cash pursuant to an award made hereunder, payment by the holder of such award of any Federal, state, local or other taxes which may be required to be withheld or paid in
connection with such award. An Agreement may provide that (i) the Company shall withhold whole shares of Common Stock which would otherwise be delivered to a holder, having an aggregate Fair Market Value determined as of the date the obligation
to withhold or pay taxes arises in connection with an award (the “Tax Date”), or withhold an amount of cash which would otherwise be payable to a holder, in the amount necessary to satisfy any such obligation or (ii) the holder
may satisfy any such obligation by any of the following means: (A) a cash payment to the Company in the amount necessary to satisfy any such obligation, (B) except for Canadian employees, delivery (either actual delivery or by attestation
procedures established by the Company) to the Company of shares of Common Stock having an aggregate Fair Market Value, determined as of the Tax Date, equal to the amount necessary to satisfy any such obligation, (C) authorizing the Company to
withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the Tax Date, or withhold an amount of cash which would otherwise be payable to a holder, equal to the amount necessary
to satisfy any such obligation, (D) in the case of the exercise of an Incentive Stock Option or Non-Qualified Stock Option, a cash payment in the amount necessary to satisfy any such obligation by a broker-dealer acceptable to the Company to
whom the optionee has submitted an irrevocable notice of exercise or (E) any combination of (A), (B) and (C), in each case to the extent set forth in the Agreement relating to the award; provided, however, that the Company shall have sole
discretion to disapprove of an election pursuant to any of clauses (B)-(E). Shares of Common Stock to be delivered or withheld may not have an aggregate Fair Market Value in excess of the amount determined by applying the minimum statutory
withholding rate. Any fraction of a share of Common Stock which would be required to satisfy such an obligation shall be disregarded and the remaining amount due shall be paid in cash by the holder. 
 6.6 Restrictions on Shares. Each award made hereunder shall be subject to the requirement that if at any time the Company
determines that the listing, registration or qualification of the shares of Common Stock subject to such award upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is
necessary or desirable as a condition of, or in connection with, the exercise or settlement of such award or the delivery of shares thereunder, such award shall not be exercised or settled and such shares shall not be delivered unless such listing,
registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company. The Company may require that certificates evidencing shares of Common Stock delivered pursuant
to any award made hereunder bear a legend indicating that the sale, transfer or other disposition thereof by the holder is prohibited except in compliance with the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 6.7 Adjustment. In the event of any stock split, stock dividend, recapitalization, reorganization, merger,
consolidation, combination, exchange of shares, liquidation, spin-off or other similar change in capitalization or event, or any distribution to holders of Common Stock other than a regular cash dividend, the number and class of securities available
under this Plan, the maximum number of shares of Common Stock with respect to which options, SARs, Stock Awards or Performance Share Awards or a combination thereof may be awarded during any calendar year to any one person, the maximum number of
shares of Common Stock that may be issued pursuant to Awards in the form of Incentive Stock Options, the number and class of securities subject to each outstanding option and the purchase price per security, the terms of each outstanding SAR, the
number and class of securities subject to each outstanding Stock Award, and the terms of each outstanding Performance Share shall be appropriately adjusted by the Committee, such adjustments to be made in the case of outstanding options and SARs
without an increase in the aggregate purchase price or base price. The decision of the Committee regarding any such adjustment shall be final, binding and conclusive. If any such adjustment would result in a fractional security being
(a) available under this Plan, such fractional security shall be disregarded, or (b) subject to an award under this Plan, the Company shall pay the holder of such award, in connection with the first vesting, exercise or settlement of such
award, in whole or in part, occurring after such adjustment, an amount in cash determined by multiplying (i) the fraction of such security (rounded to the nearest hundredth) by (ii) the excess, if any, of (A) the Fair Market Value on
the vesting, exercise or settlement date over (B) the exercise price, if any, of such award. 
  

 13 

 6.8 Change in Control.  
 (a) (1) Notwithstanding any provision in this Plan or any Agreement, in the event of a Change in Control pursuant to Section (b)(3)
or (4) below in connection with which the holders of Common Stock receive shares of common stock that are registered under Section 12 of the Exchange Act, (i) all outstanding options and SARS shall immediately become exercisable in
full, (ii) the Restriction Period applicable to any outstanding Restricted Stock Award shall lapse, (iii) the Performance Period applicable to any outstanding Performance Share shall lapse, unless otherwise provided in the award Agreement
and subject to the discretion of the Committee, (iv) the Performance Measures applicable to any outstanding award shall be deemed to be satisfied at the maximum level and (v) there shall be substituted for each share of Common Stock
available under this Plan, whether or not then subject to an outstanding award, the number and class of shares into which each outstanding share of Common Stock shall be converted pursuant to such Change in Control. In the event of any such
substitution, the purchase price per share in the case of an option and the base price in the case of an SAR shall be appropriately adjusted by the Committee (whose determination shall be final, binding and conclusive), such adjustments to be made
in the case of outstanding options and SARs without an increase in the aggregate purchase price or base price. 
 (2)
Notwithstanding any provision in this Plan or any Agreement, in the event of a Change in Control pursuant to Section (b)(1) or (2) below, or in the event of a Change in Control pursuant to Section (b)(3) or (4) below in connection with
which the holders of Common Stock receive consideration other than shares of common stock that are registered under Section 12 of the Exchange Act, each outstanding award shall be surrendered to the Company by the holder thereof, and each such
award shall immediately be canceled by the Company, and the holder shall receive, within ten days of the occurrence of a Change in Control, a cash payment from the Company in an amount equal to (i) in the case of an option, the number of shares
of Common Stock then subject to such option, multiplied by the excess, if any, of the greater of (A) the highest per share price offered to stockholders of the Company in any transaction whereby the Change in Control takes place or (B) the
Fair Market Value of a share of Common Stock on the date of occurrence of the Change in Control, over the purchase price per share of Common Stock subject to the option, (ii) in the case of a Free-Standing SAR, the number of shares of Common
Stock then subject to such SAR, multiplied by the excess, if any, of the greater of (A) the highest per share price offered to stockholders of the Company in any transaction whereby the Change in Control takes place or (B) the Fair Market
Value of a share of Common Stock on the date of occurrence of the Change in Control, over the base price of the SAR, (iii) in the case of a Restricted Stock Award or Performance Share Award, the number of shares of Common Stock or the number of
Performance Shares, as the case may be, then subject to such award, multiplied by the greater of (A) the highest per share price offered to stockholders of the Company in any transaction whereby the Change in Control takes place or (B) the
Fair Market Value of a share of Common Stock on the date of occurrence of the Change in Control. In the event of a Change in Control, each Tandem SAR shall be surrendered by the holder thereof and shall be canceled simultaneously with the
cancellation of the related option. The Company may, but is not required to, cooperate with any person who is subject to Section 16 of the Exchange Act to assure that any cash payment in accordance with the foregoing to such person is made in
compliance with Section 16 and the rules and regulations thereunder. 
 (b) “Change in Control” shall mean:

 (1) the acquisition by any individual, entity or group (a “Person”), including any “person”
within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act, of beneficial ownership within the meaning of Rule 13d-3 promulgated under the Exchange Act, of more than 50% of either (i) the then outstanding shares of common stock
of the Company (the “Outstanding Common Stock”) or (ii) the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Voting
Securities”); excluding, however, the following: (A) any acquisition directly from the Company (excluding any acquisition resulting from the exercise of an exercise, conversion or exchange privilege unless the security being so
exercised, converted or exchanged was acquired directly from the Company), (B) any acquisition by the Company, (C) any acquisition by an employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation
controlled by the Company or (D) any 

  

 14 

 
acquisition by any corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (3) of this
Section 6.8(b); provided further, that for purposes of clause (B), if any Person (other than the Company or any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company) shall
become the beneficial owner of more than 50% of the Outstanding Common Stock or more than 50% of the Outstanding Voting Securities by reason of an acquisition by the Company, and such Person shall, after such acquisition by the Company, become the
beneficial owner of any additional shares of the Outstanding Common Stock or any additional Outstanding Voting Securities and such beneficial ownership is publicly announced, such additional beneficial ownership shall constitute a Change in Control;

 (2) individuals who, as of the beginning of any consecutive 2-year period constitute the Board of Directors (the
“Incumbent Board”) cease for any reason to constitute at least a majority of such Board; provided that any individual who subsequently becomes a director of the Company and whose election, or nomination for election by the
Company’s stockholders, was approved by the vote of at least a majority of the directors then comprising the Incumbent Board shall be deemed a member of the Incumbent Board; and provided further, that any individual who was initially elected as
a director of the Company as a result of an actual or threatened solicitation by a Person other than the Board for the purpose of opposing a solicitation by any other Person with respect to the election or removal of directors, or any other actual
or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board shall not be deemed a member of the Incumbent Board; 
 (3) the consummation of a reorganization, merger or consolidation of the Company or sale or other disposition of all or substantially all of the assets of the Company (a “Corporate Transaction”);
excluding, however, a Corporate Transaction pursuant to which (i) all or substantially all of the individuals or entities who are the beneficial owners, respectively, of the Outstanding Common Stock and the Outstanding Voting Securities
immediately prior to such Corporate Transaction will beneficially own, directly or indirectly, more than 50% of, respectively, the outstanding shares of common stock, and the combined voting power of the outstanding securities of such corporation
entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Corporate Transaction (including, without limitation, a corporation which as a result of such transaction owns the Company or all or
substantially all of the Company’s assets either directly or indirectly) in substantially the same proportions relative to each other as their ownership, immediately prior to such Corporate Transaction, of the Outstanding Common Stock and the
Outstanding Voting Securities, as the case may be, (ii) no Person (other than: the Company; any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company; the corporation
resulting from such Corporate Transaction; and any Person which beneficially owned, immediately prior to such Corporate Transaction, directly or indirectly, more than 50% of the Outstanding Common Stock or the Outstanding Voting Securities, as the
case may be) will beneficially own, directly or indirectly, more than 50% of, respectively, the outstanding shares of common stock of the corporation resulting from such Corporate Transaction or the combined voting power of the outstanding
securities of such corporation entitled to vote generally in the election of directors and (iii) individuals who were members of the Incumbent Board will constitute at least a majority of the members of the board of directors of the corporation
resulting from such Corporate Transaction; or 
 (4) the consummation of a plan of complete liquidation or dissolution of the
Company. 
 (5) Notwithstanding the foregoing, a Change in Control under the Plan shall not be deemed to have occurred as a
result of the implementation of the Sixth Amended Joint Plan of Reorganization for Owens Corning and Its Affiliated Debtors and Debtors-In-Possession (As Modified), which was confirmed by the United States Bankruptcy Court for the District of
Delaware on September 26, 2006, or any restructuring of the Company associated with the implementation of the Plan of Reorganization. 
 6.9 No Right of Participation or Employment. No person shall have any right to participate in this Plan. The Committee’s selection of a person to participate in this Plan at any time shall not require the
Committee to select such person to participate in this Plan at any other time. Neither this Plan nor any award made hereunder 

  

 15 

 
shall confer upon any person any right to continued employment by the Company, any Subsidiary or any affiliate of the Company or affect in any manner the
right of the Company, any Subsidiary or any affiliate of the Company to terminate the employment of any person at any time without liability hereunder. 
 6.10 Rights as Stockholder. No person shall have any right as a stockholder of the Company with respect to any shares of Common Stock or other equity security of the Company which is
subject to an award hereunder unless and until such person becomes a stockholder of record with respect to such shares of Common Stock or equity security. 
 6.11 Stock Certificates. To the extent that this Plan provides for issuance of certificates to reflect the issuance of shares of Common Stock, the issuance may be effected on a
noncertificated basis, to the extent not prohibited by applicable law or the rules of the New York Stock Exchange. 
 6.12
Governing Law. This Plan, each award hereunder and the related Agreement, and all determinations made and actions taken pursuant thereto, to the extent not otherwise governed by the Code or the laws of the United States,
shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws. 
  

 16Exhibit 10.1

 Exhibit 10.1 
 December 4, 2007 
 Biotest Pharmaceuticals Corporation 
 c/o Biotest AG 
 Landsteinerstr. 5 
 63303 Dreieich

 Germany 
 Biotest AG 
 Landsteinerstr. 5 
 63303 Dreieich 
 Germany 
 RE: Letter Agreement Regarding Interim Operations and
Regulatory Arrangements 
 Ladies and Gentlemen: 
 Reference is made to that certain Asset Purchase Agreement by and among Nabi Biopharmaceuticals (“Nabi”), Biotest Pharmaceuticals Corporation (“Biotest”) and Biotest AG (“Parent”; and
together with Nabi and Biotest, the “Parties”), dated as of September 11, 2007, as amended from time to time (the “Purchase Agreement”). Capitalized terms used in this letter agreement that are not defined
herein have the meanings assigned to such terms in the Purchase Agreement. The Parties hereby agree as follows: 
 1. Operations Pending Issuance of Florida Licenses. The manufacture, marketing, distribution, and sale of Nabi-HB® at the current establishment (the
“Licensed Business”) shall continue to be operated under Nabi’s oversight and control in full accordance with and pursuant to Nabi’s Florida manufacturing and wholesale distributor licenses (the “Nabi Florida
Licenses”) during the period (the “Interim Period”) from and after the Effective Time until Biotest is issued a Florida manufacturing license and prescription drug wholesale distributor license (collectively, the
“Biotest Florida Licenses”) and consistent in all material respects with Nabi’s past practices and procedures. 
  

	 	a.	Oversight and Control Over Licensed Business. During the Interim Period, Nabi shall continue to have oversight and control authority over the Licensed Business including with
respect to the Nabi Florida Licenses and the compliance of the Licensed Business with all requirements and obligations thereunder. Biotest and all Biotest employees shall comply in all respects with requests and/or instructions of Nabi in the
exercise of Nabi’s oversight and control authority hereunder. 

  

	 	b.	 Meetings, Coordination and Reporting. Representatives of Nabi and Biotest shall meet regularly (no less frequently than once per week) as necessary to
coordinate with respect to Nabi’s oversight and control authority and with respect to Nabi’s responsibility for Florida regulatory compliance and transition matters. Each such Party shall 

	 	 
promptly (i) provide the other with copies of all correspondence between such Party and the Florida Department of Health (“FDOH”) and
any other Governmental Authority involved in administration of the Nabi Florida Licenses and (ii) inform the other Party of material events or occurrences relating to compliance with the Nabi Florida Licenses. 

  

	 	c.	Nabi Corporate Officer. Nabi’s Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer, Jordan I. Siegel, will remain an employee and
officer of Nabi during the Interim Period and shall be based at 5800 Park of Commerce Blvd., NW, Boca Raton, FL, the facility where the Licensed Business is conducted (the “Facility”). Mr. Siegel shall have principal on-site
authority for exercising on behalf of Nabi the oversight and control authority described herein during the Interim Period. 

  

	 	 d.
	 Ownership of Nabi-HB Inventory, WIP, And API. Notwithstanding anything to the contrary contained in the Purchase
Agreement or the Other Agreements, Nabi shall retain title to the Nabi-HB® Finished Goods, Nabi-HB WIP, and Nabi-HB raw materials (collectively, “Nabi-HB Inventory”) until
such time as the Biotest Florida Licenses are issued (which for purposes of this Agreement shall also encompass any alternative means, authorized by the relevant Florida State Governmental Authorities, of granting to Biotest authority necessary
under Florida law to own the Nabi-HB Inventory). All labeled Nabi-HB Inventory shall retain its current Nabi labeling until Biotest obtains all applicable approvals for new Biotest labeling and the Biotest Florida Licenses are issued. During the
Interim Period, Nabi shall not allow any Encumbrances on the Nabi-HB Inventory other than Permitted Encumbrances. Upon issuance of the Biotest Florida Licenses, Nabi will convey to Biotest all of its right, title and interest in the Nabi-HB
Inventory that has not, prior to that time, been sold in accordance with Section 1.e below. 

  

	 	e.	Nabi Maintenance Of Nabi Florida Licenses. During the Interim Period, Nabi shall correct, if necessary, its pending Florida state wholesalers license application and respond
to any requests or questions raised by the State of Florida and shall use commercially reasonable efforts to maintain and keep in full force and effect the Nabi Florida Licenses and to. 

  

	 	f.	Marketing, Distribution and Sale of Nabi-HB. During the Interim Period, all marketing, distribution, and sales of Nabi-HB Inventory shall be conducted by Nabi. When orders
for Nabi-HB are received Nabi will cause such orders to be fulfilled and invoiced in Nabi’s name in the same manner as prior to the Effective Time, provided that remittance instructions shall be to Nabi in a manner reasonably acceptable to
Biotest, with payout to Biotest in accordance with the reconciliation provisions of Section 1.g hereof when the Biotest Florida Licenses are issued. During the Interim Period, Biotest shall comply with the requests and/or instructions of
Nabi that Nabi believes in good faith to be necessary in order to ensure that the conduct of Nabi-HB marketing, distribution, and sales activities comports with Federal and State law and the obligations of both Nabi and Biotest thereunder.

	 	g.	Rights to Trademarks and Promotional Materials. Nabi shall retain rights to the Promotional Materials and BSBU Marks as necessary to effectuate the purposes of this Agreement
and comply with the Nabi Florida Licenses. Biotest shall not use the Promotional Materials or BSBU Marks until the Biotest Florida Licenses are issued. 

  

	 	h.	Operation for the Account of Biotest; Reconciliation Activities. Nabi’s operation of the Licensed Business during the Interim Period shall be for the ultimate financial
benefit of Biotest in order to give effect to the Parties’ intentions under the Purchase Agreement. Accordingly, all revenues and expense of operation of the Licensed Business from and after the Effective Time shall be for the account of
Biotest. The Parties shall conduct a periodic reconciliation, no less frequently than once per week, to ensure that revenues and expenses relating to the operation of the Licensed Business during the Interim Period are properly allocated to Biotest.
Such reconciled revenues shall be paid or received by Biotest when the Biotest Florida Licenses are issued. 

 2. Interim
Oversight With Respect to Federal Registrations. From the Closing until the transfers of Nabi’s federal Registrations to Biotest are authorized and all federal licenses issued or transferred to Biotest, Nabi shall have oversight and control
authority over the elements of Biotest’s post-Closing operations that are subject to such Registrations (to the extent that authorization for transfer has not been received) as necessary or as mandated by FDA in connection with the compliance
of such operations with the requirements of such Registrations. Biotest shall comply in all respects with requests and/or instructions of Nabi in the exercise of Nabi’s oversight and control authority hereunder. 
 3. Indemnification. Biotest shall indemnify and defend the Seller Indemnitees against, and agrees to hold them harmless from, any Losses sustained
or incurred (payable promptly upon written request by any Seller Indemnitee), to the extent arising from, in connection with, or otherwise with respect to acts or omissions by or on behalf of Nabi relating to this Agreement and the activities
contemplated hereunder, provided, however, that Biotest shall not be required to indemnify any Person, and shall not have any liability under this Section 3 to the extent the liability or obligation is directly caused by
the gross negligence or willful misconduct of any Seller Indemnitee. Except as expressly provided herein, indemnification of Seller Indemnitees hereunder shall be governed by Article XI and other applicable provisions of the Purchase
Agreement as if the indemnification were of Losses with respect to an Assumed Liability. 
 4. Nabi CFO. Mr. Siegel shall remain
as an employee of Nabi in the position of Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer from the Effective Time through March 28, 2008 unless Mr. Siegel resigns or is terminated by Nabi. During
such time, Mr. Siegel may accept simultaneous appointment as Chief Financial Officer of Biotest and may perform the duties of that position to the extent that such duties do not unreasonably interfere with Mr. Siegel’s duties to Nabi.
Biotest may announce the appointment of Mr. Siegel as its Chief Financial Officer from and after the Effective Date. Nabi shall pay Mr. Siegel’s compensation during such period in accordance with his existing employment agreement. In
the event that Mr. Siegel determines that there is an actual or potential conflict between his duties to Nabi and his duties to Biotest with respect to any matter or issue, Mr. Siegel shall promptly inform the Chief Executive Officers of Nabi
and Parent and their mutual determination with respect 

 
to such conflict shall control. If the conflict cannot be resolved in the foregoing manner, either Party may refer the conflict to arbitration in accordance
with Section 12.8 of the Purchase Agreement. Pending resolution of the conflict, Mr. Siegel shall not have a duty to either Nabi or Biotest with respect to the matter or issue. In any such circumstance, Nabi shall as soon as
reasonably possible appoint another Nabi officer who shall have principal on-site authority for exercising on behalf of Nabi the oversight and control authority described herein during the Interim Period. Biotest hereby confirms for the benefit of
Mr. Siegel that his continued employment by Nabi pursuant to this Section 4 will not constitute grounds for termination for cause under his employment agreement with Biotest. Nabi hereby confirms for the benefit of Mr. Siegel
that his employment by Biotest pursuant to this Section 4 will not constitute grounds for termination for cause under his Employment Agreement with Nabi dated April 29, 2006 and that his continued employment by Nabi will not effect his
status as an “affected employee” for purposes of certain benefits to which he is eligible as a result of the closing of the transactions contemplated by the Purchase Agreement. 
 5. Mutual Waiver of Certain Purchase Agreement Provisions. Each Party waives any breach by the other Party of a representation, warranty or
covenant of such other Party under the Purchase Agreement or any Other Agreement that occurs as a direct result of such other Party’s performance of its obligations under this Agreement. 
 6. Incorporation by Reference of Certain Provisions of Purchase Agreement. Except as specifically provided herein or unless the context requires
otherwise, Article XII of the Purchase Agreement is hereby incorporated by reference herein as if set out at length herein, and shall be read to apply to this letter agreement standing on its own. 
 7. Controlling Document. In the event of any inconsistency between the terms of this letter agreement and any term of the Purchase Agreement or
any Other Agreement, the terms of this letter agreement shall govern. 
 [signature page follows] 

 If the foregoing reflects your understanding with respect to the subject matter of this letter agreement,
please acknowledge your agreement with and acceptance of the same by signing the enclosed counterpart of this letter in the space provided below and returning it to the undersigned. 
  

			
	Very truly yours,
	
	NABI BIOPHARMACEUTICALS
		
	By:	 	 /s/ Leslie Hudson, Ph.D.

	Name:	 	Leslie Hudson, Ph.D.
	Title:	 	President and Chief Executive Officer

 Acknowledged and agreed as of the date first written above: 
  

			
	BIOTEST PHARMACEUTICALS CORPORATION
		
	By:	 	 /s/ Dr. Michael Ramroth

	Name:	 	Dr. Michael Ramroth
	Title:	 	President
	
	BIOTEST AG
		
	By:	 	 /s/ Martin Reineke, POA

	Name:	 	Dr. Gregor Schulz
	Title:	 	Chief Executive Officer
		
	By:	 	 /s/ Dr. Michael Ramroth

	Name:	 	Dr. Michael Ramroth
	Title:	 	Chief Financial Officer

  

	cc:	Kaye Scholer LLC 

 Attention: Russell Pallesen

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]